Spotlight on Monoclonal Antibodies in Multiple Myeloma

Slides:

Advertisements

Similar presentations

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

Advertisements

A Phase Ib Dose Escalation Trial of SAR (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Applying Biosimilars in Hematologic Cancers

Hot Off the Press: Changes in the Landscape of Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Relapsed/Refractory Follicular Lymphoma Conundrums

Progression After Cancer Immunotherapy in Advanced NSCLC

Selecting Therapy for Relapsed/ Refractory Multiple Myeloma

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

The HCV Revolution: Are You and Your Practice Ready?

Prolonging Progression-Free Survival in Follicular Lymphoma

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Current and Future Goals in the Treatment of Relapsed CLL

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Optimizing Management of Advanced Bladder Cancer

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Treatment Decisions in Chemorefractory Follicular Lymphoma

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Diagnostic and Management Challenges in Patients With Chronic Migraine

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Multiple Myeloma

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

CGRP Antibodies in Migraine

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Personalizing Management in the Care of Patients With Advanced Sarcoma

Breaking New Ground With Migraine Prevention Therapies

Approaches in Newly Diagnosed Multiple Myeloma: When and What

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Myeloid Updates From the Summer Congresses

Getting to Grips With the Science of CGRP and Migraine

New Classes of Therapy in Multiple Myeloma

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Rising Cost of Healthcare and Potential Impact of Biosimilars

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

The Role of Maintenance Therapy in Multiple Myeloma

Evaluating BTK Inhibitors in CLL

Patient and Clinician Perspectives on Preventive Therapy for Migraine

On the Cusp: New Approaches for Multiple Myeloma

Phase III MAIA: Daratumumab + Len/Dex vs Len/Dex in Transplantation-Ineligible Newly Diagnosed Multiple Myeloma Integrating New Malignant Hematology Findings.

Novel Concepts in the Management of RCC

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

From Adjuvant to Metastatic in Melanoma

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Spotlight on Monoclonal Antibodies in Multiple Myeloma

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Overview

Daratumumab Phase 1/2 Data

Elotuzumab: Phase 1/2 Data

mAb Combination Therapy, Early Relapse Trials Daratumumab

mAb Combination Therapy, Early Relapse Trials Elotuzumab

Limitations of Early Relapse Trials POLLUX

Dara/Pom/Dex in R/R MM Utility of Daratumumab Retreatment in 1st Relapse

Phase 3 OPTIMISMM Trial (Pom/Bort/Dex) PFS in Patients With 1 Prior Line of Therapy

mAb Indications in Previously Treated Patients With MM

APOLLO (Phase 3) Pom/Dex +/- Dara in R/R MM

ELOQUENT-3 Elo + Pom/Dex for R/R MM

Treatment After CD38-mAb Failure

Integrating Dara and Elo Into MM Therapy Proposed Simplified mAb Infusion Algorithm

Dosing Considerations

ALCYONE Dara + VMP for Untreated MM

Dara + Len/dex (D-Rd) vs Rd in Transplant-Ineligible NDMM: MAIA

Open Questions

Future Directions

Abbreviations

Abbreviations (cont)